The Relation of GnRH Treatment to QTc Interval in Transgender Females
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Mar 7, 2017
Trial Information
Current as of May 19, 2025
Terminated
Keywords
ClinConnect Summary
This study is a quasi-experimental time series study, designed to examine the relation between GnRH agonist treatment for 6 months in transgender female youth and electrocardiographic change in QTc interval. Study subjects will be identified when visiting the UCSF Child and Adolescent Gender Center (CAGC). A baseline electrocardiogram (ECG) will be obtained in clinic before initiation of GnRH agonist treatment and at the 6 months follow up appointment.
Sampling scheme: Consecutive sample of transfemale patients presenting to UCSF CAGC (Child and Adolescent Gender Center) clinics meeting en...
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • 1. Transgender males to females in pubertal stage Tanner stage 4-5
- • 2. starting GnRH agonist treatment
- Exclusion Criteria:
- • 1. Heart disease or arrhythmias at base line
- • 2. Electrolyte abnormalities at baseline (abnormal serum levels of calcium, potassium or magnesium)
- • 3. Failure to obtain informed consent from a parent or guarding or informed assent from a youth.
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials